Hemoglobinopathy Market to Nearly Double to USD 20.7 Billion by 2030, Fueled by Gene Therapy and Expanded Screening Uptake

Mordor Intelligence has published a new report on hemoglobinopathy treatment market offering a comprehensive analysis of trends, growth drivers, and future projection



Introduction

The hemoglobinopathy treatment market size stood at USD 10.2 billion in 2025 and is forecast to climb to USD 20.7 billion by 2030, translating to a 12.6% CAGR. This forecast underscores the increasing demand for effective treatments for genetic blood disorders such as sickle cell disease and β-thalassemia. As adoption expands globally, especially in regions with high disease prevalence and increasing newborn screening programs, this market is set to see accelerated growth and deeper penetration across treatment and diagnostic segments.

The growing burden of hemoglobinopathies worldwide, combined with advancements in therapeutic and diagnostic technologies, is reshaping how care is delivered. More patients are gaining access to cutting-edge therapies and early diagnosis, which together are driving the expansion of the hemoglobinopathy market.

Report Overview:

https://www.mordorintelligence.com/industry-reports/hemoglobinopathy-market?utm_source=openpr

Key Trends

Rise of Gene-Editing Therapies
One of the most influential trends shaping the hemoglobinopathy market is the accelerating adoption of gene-editing therapies. With the regulatory approval of first-in-class treatments that address the underlying genetic cause of hemoglobinopathies rather than simply managing symptoms, healthcare systems are showing stronger support for curative options. This shift in payer and provider willingness is enabling movement away from lifelong supportive care models.

Expansion of Newborn-Screening Programs
Global expansion of newborn-screening programs is another pivotal driver. As more countries implement mandatory or widely encouraged screening for hemoglobin variants, detection rates are rising sharply, particularly in regions where diagnostic access was historically limited. This surge in early identification brings more patients into clinical pathways, effectively increasing the total addressable population.

Growth of Molecular Genetic Diagnostic Testing
Diagnostics are also witnessing a transformation. While traditional tests such as hemoglobin electrophoresis remain relevant, molecular genetic testing is rapidly gaining market share. Improved accessibility, reduced costs, and the ability to detect a wider range of hemoglobin disorders, including rare variants, are making genetic-based diagnostics increasingly preferred. This trend supports earlier intervention and stronger long-term outcomes.

Geographic Shifts in Patient Volumes
A notable shift is emerging in the geographic distribution of patient volumes. North America continues to generate substantial revenue due to rapid adoption and high-value therapies, but Asia-Pacific is now delivering the largest increase in absolute patient numbers. National disease-reduction initiatives, improved awareness, and broader access to affordable molecular diagnostics are key factors contributing to this regional surge.

Market Segmentation

The hemoglobinopathy market can be viewed through several core segments: disease type, therapy type, diagnostic technique, and end-user. Key insights include:

By Disorder Type

Sickle Cell Disease (SCD)

Beta-Thalassemia

Alpha-Thalassemia

Other Hemoglobin Variants (Hb C, Hb E, etc.)

By Therapy Type

Pharmacological Agents

Gene Therapy

Bone-Marrow / Stem-Cell Transplant

Blood Transfusion & Iron Chelation

By Diagnosis Technique

Hemoglobin Electrophoresis

High-Performance Liquid Chromatography (HPLC)

Molecular Genetic Testing (PCR / NGS)

Point-of-Care Rapid Tests

Others

By End User

Hospitals

Specialty Clinics & Transfusion Centers

Diagnostic Laboratories

Academic & Research Institutes

By Geography

North America

Europe

Asia-Pacific

Middle East & Africa

South America

Key Players

Pfizer Inc.

Novartis

Bluebird Bio

Vertex Pharmaceuticals

Bristol Myers Squibb

At the same time, diagnostic companies and clinical laboratories are expanding capabilities for molecular testing and hemoglobin sub-typing, reflecting increased demand for early identification and comprehensive diagnostics. This broadened diagnostic infrastructure is supporting overall market growth, as more patients are diagnosed, referred, and treated.

Conclusion

The hemoglobinopathy market stands at the cusp of significant expansion. With the global market size expected to nearly double by 2030, driven by rising availability of gene therapies, expanded newborn-screening programs, better diagnostics, and a growing patient base, the outlook is optimistic.

As treatment paradigms shift from supportive care to curative therapies, and as access improves in high-prevalence regions, the demand for both diagnostic and therapeutic solutions will continue to rise. This growth reflects not just an increase in prevalence or detection, but a broader global push toward addressing genetic blood disorders comprehensively.

For complete market analysis, please visit the Mordor Intelligence page:

https://www.mordorintelligence.com/industry-reports/hemoglobinopathy-market?utm_source=openpr

Industry related Reports:

Spine Biologics Market: The Spine Biologics Market is Segmented by Product Type (Bone Graft Substitutes [Bone Morphogenetic Proteins and More], Spinal Allografts [Machined Structural Allografts and More], Cell-Based Matrices, and More), Surgery Type (Anterior Cervical Discectomy & Fusion and More), End-User (Hospitals and More), and Geography (North America, Europe, and More).

Get more Insights: https://www.mordorintelligence.com/industry-reports/spine-biologics-market?utm_source=openpr

T-cell Immunotherapy Market: The T-Cell Immunotherapy Market is Segmented by Therapy Type (CAR-T, TCR-T, TIL, Γδ T-Cell, Others), Indication (Hematologic Malignancies, Solid Tumors, Autoimmune Diseases, Viral Infections, Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, South America).

Get more Insights: https://www.mordorintelligence.com/industry-reports/t-cell-immunotherapy-market?utm_source=openpr

Specialty Pharmaceuticals Market: The Specialty Pharmaceuticals Market Report is Segmented by Application (Oncology, Immunology, Endocrinology, Infectious Diseases, Neurology), Drug Class (Biologics, Small-Molecule Specialty Drugs), Mode of Administration (Injectable/Parenteral, Oral, Other), and Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa).

Get more Insights:: https://www.mordorintelligence.com/industry-reports/specialty-pharmaceuticals-market?utm_source=openpr

About Mordor Intelligence:

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.

With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.

Mordor Intelligence, 11th Floor, Rajapushpa Summit, Nanakramguda Rd, Financial District, Gachibowli, Hyderabad, Telangana - 500032, India

For any inquiries or to access the full report, please contact:

media@mordorintelligence.com
https://www.mordorintelligence.com/

This release was published on openPR.